26 / 32
Cut-off date: 31 May 2018
Note: Patients (n=6) without matched pre/post therapy scans were excluded from the plot
Entrectinib activity in
NTRK
fusion-positive solid tumours:
Individual patient responses by CNS mets status at baseline
CNS mets at baseline (n=12)
No CNS mets at baseline
(n=42)
ORR
(95% CI)
50.0%
(21.1–78.9)
59.5%
(43.3–74.4)
0
-30
-50
-90
15
-80
-70
-60
-40
-20
-10
20
30
40
-100
50
CNS mets at baseline
No CNS mets at baseline
Results per Blinded Independent Central Review (BICR)
Best % change from baseline